We envision a world where no one has to die of tuberculosis. However, this cannot be achieved without new, better, and faster-acting tuberculosis drug regimens. The Global Alliance for TB Drug Development (TB Alliance) was established in 2000 as a not-for-profit product development partnership to lead the search for new TB regimens and catalyze global efforts for new TB regimens that can bring hope, and health, to millions.
TB is one of the world's deadliest pandemic diseases and is becoming increasingly resistant to current drugs. Only with faster, better and affordable cures for tuberculosis can we save millions of lives and overcome this global epidemic. TB kills 1.4 million people each year or more than one person every 25 seconds. Propelled by global poverty, the AIDS epidemic, and drug resistance, the global threat of TB is greater than ever.
1.4 Million People Every Year
Over 3,800 Every Day
One Person Every 25 Seconds
Despite attempts to bolster global TB control efforts, the current TB treatment is simply impractical and inadequate to address today's complex epidemic.
We need faster-acting tools to treat TB in all forms, wherever it may strike around the world.
Since it's inception in 2000, the TB Alliance has been making leaps of progress toward this goal.
Before the TB Alliance was established, there were no clinical-stage TB drug candidates being developed, let alone realistic hope for novel TB drug regimens. Today, working with a broad range of public and private stakeholders, including pharmaceutical companies, universities, and other research laboratories around the world, the TB Alliance is leading the advancement of the most comprehensive portfolio of TB drug candidates in history. From this global network, the TB Alliance leverages the most promising science to advance new TB drug regimens that are needed to fight this pandemic.
We are driven by the needs of TB patients around the world, and committed to ensuring that approved new regimens are affordable, adopted and available to those who need them. To ensure our products reach the hands of those who need them most urgently, the TB Alliance and its partners are working with global, regional, and national stakeholders to facilitate regulatory approval, adoption by TB programs, and widespread availability of new drug regimens.